Clinical Trials Directory

Trials / Completed

CompletedNCT02025816

RNAseq Analysis of Microbial Gene Expression in Necrotizing Soft Tissue Infections

Status
Completed
Phase
Study type
Observational
Enrollment
35 (actual)
Sponsor
Texas Tech University Health Sciences Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Hypothesis: We hypothesize that RNAseq will allow us to learn more about the causative agents of necrotizing soft tissue infections (NSTI) and risk factors involved in acquiring these devastating infections Tissue biopsies will be obtained from consented patients admitted with NSTI. Biopsies will be used for standard clinical analysis of bacterial species present or stored for later RNA sequencing. RNA sequencing will identify bacteria that are present within the infection site that may not be detected using standard culture techniques as well as reveal bacterial gene expression profiles within the NSTI site. Medical charts will also be reviewed for basic patient information as well as wound care management practices. We hope to identify bacterial species commonly present in these types of infections as well as risk factors predisposing individuals to NSTI's.

Conditions

Timeline

Start date
2013-12-01
Primary completion
2017-09-01
Completion
2019-06-01
First posted
2014-01-01
Last updated
2019-12-09

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT02025816. Inclusion in this directory is not an endorsement.

RNAseq Analysis of Microbial Gene Expression in Necrotizing Soft Tissue Infections (NCT02025816) · Clinical Trials Directory